Lamarca/Martinez-Useros
Clinical research
Institute for Health Research Jimenez Diaz Foundation
·Madrid ·

Dr. Ángela Lamarca is a Medical Oncologist (MD, PhD, MSc), specialized in gastrointestinal malignancies (hepatopancreaticobiliary (HPB) and neuroendocrine tumors (NET)). He completed his training in Medical Oncology (including his PhD) in Spain (Hospital Universitario La La Salto, Madrid). He moved to The Christie NHS Foundation Trust (Manchester, UK) in 2013, where he completed a 4-year fellowship program in HPB and NET. Dr. Lamarca has a Master’s degree in Molecular Biology of Cancer and a second Master’s degree in Biostatistics. She was awarded the American Society of Clinical Oncology (ASCO) Conquer Cancer Foundation Young Investigator Award in 2017 and was appointed Consultant in Medical Oncology at The Christie NHS Foundation Trust in May 2018, where she practiced until May 2022, when she returned. to Madrid (Spain; Hospital Universitario Fundación Jiménez Díaz) to continue his clinical and research activities in BPH and NET. Dr. Angela Lamarca is currently a member of the ESMO Council, chair of the ESMO Press and Media Affairs Working Group and a member of the ESMO Gastrointestinal Cancer Faculty Group, Department of Upper Digestive. She is also chair of the EORTC Hepatobiliary Gastrointestinal Cancer Group and a member of the ENETS Advisory Board and the ENS-CCA Steering Committee. His main interest in the field of pancreatic cancer is based on the development of biomarkers for personalized treatment and the design of clinical treatments. trials aimed at improving treatment options for future patients.

Here, Dr. Javier Martínez-Useros has been working on a full contract basis since the research group moved from the Clínica Universidad de Navarra (Pamplona, Spain) to the FIIS-FJD in 2012. Dr. Javier Martínez-Useros is fully devoted to applied and translational research. research on gastroenteropancreatic tumors, especially pancreatic adenocarcinoma (PDAC) and metastatic colorectal cancer (mCRC). His research focuses, on the one hand, on the discovery of early diagnostic biomarkers detectable by liquid biopsies. On the other hand, its objective is to find new therapeutic targets and novel treatments to improve the response rate and survival of cancer patients. In this sense, Dr. Javier Martínez-Useros has 45 scientific articles published in high impact journals (Cancer Cell, Br J Cancer, Intl J Cancer, Cancers, J Clin Med, etc.). He is also principal investigator of a project for a novel treatment strategy based on exosomes as chemocarriers (https://aespanc.es/ganadores-5a-beca-carmen-delgado-miguel-perez-mateo/), and has been awarded multiple national project grants (PEJ-2020-TL/BMD-19339; (PEJD-2018-PRE/BMD-8398). Academically, he is Associate Professor at the Universidad Rey Juan Carlos and has directed 2 PhD Theses (2 more in progress), 27 master projects and is currently a member of the Animal Welfare Committee of the FIIS-FJD.

Main publications in pancreatic cancer:

  1. Li W, Gonzalez-Gonzalez M, Sanz-Criado L, et al J. A Novel PiRNA Enhances CA19-9 Sensitivity for Pancreatic Cancer Identification by Liquid Biopsy. J Clin Med. 2022 Dec 9;11(24):7310. doi: 10.3390/jcm11247310.
  2. Martinez-Useros J, Martin-Galan M, Garcia-Foncillas J. et al The Match between Molecular Subtypes, Histology and Microenvironment of Pancreatic Cancer and Its Relevance for Chemoresistance.Cancers (Basel). 2021 Jan 17;13(2):322. doi: 10.3390/cancers13020322.
  3. Lindsay Esther Carnie, Dinakshi Shah, Kate Vaughan, et al. Prospective observational study of prevalence, assessment and treatment of pancreatic exocrine insufficiency in patients with inoperable pancreatic malignancy (PANcreatic cancer Dietary Assessment - PanDA). Cancers 2022.
Angela Lamarca

Principal Investigator

Group members

  • Angela Lamarca
  • Javier Martinez-Useros

Other groups